BioSpace News Archive

Mirum Pharmaceuticals, Inc. announced that on February 10, 2021, the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 21,500 shares of common stock to three new employees under Mirum’s 2020 Inducement Plan.

Company to discuss study results and present corporate overview at SMi’s 12th Annual RNA Therapeutics Virtual Conference on February 11

Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the underwriter of its previously announced underwritten public offering of ordinary shares,

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced results from the Phase 3 randomized controlled trial of its allogeneic mesenchymal precursor cell therapy rexlemestrocel-L in 404 enrolled patients with chronic low back pain due to degenerative disc disease refractory to conventional treatments.

Transcenta Holding Limited (Transcenta), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the appointment of Dr. Michael Shi as Executive Vice President, Head of Global R&D and Chief Medical Officer.

Cigna’s International Markets business published the fifth edition of its COVID-19 Global Impact Study, which highlights the contrast in well-being around the world as vaccine roll-out commenced for some, while other markets anticipated vaccine approvals to come.

Bioventus Inc. announced the pricing of its initial public offering of 8,000,000 shares of Class A common stock at a public offering price of $13.00 per share.

Skin cooling systems work by chilling the skin layer, thereby minimizing the pain at the injury or pain point.

Fact.MR, a global research & consulting firm, in their updated edition of the report, projected that the canine influenza treatment market is poised to witness a robust growth in 2021 & beyond.

Fact.MR, a global research & consulting firm, in their updated edition of the report, projected that the kick bucket market will foresee a moderate CAGR in 2021 & beyond.